

American Society of Hematology (ASH) Annual Meeting 2021

December 11-14, 2021

Authors	Title	Presentation Type	Date	Session	Link
<p>Derek Tang^{1*}, Parameswaran Hari², Karthik Ramasamy³, Katja Weisel^{4*}, Prashant Joshi, MD⁵, Liang Liu, MS^{6*}, Min Che^{1*}, Gabriela Hernandez^{5*}, Rafat Abonour, MD⁶, James W. Hardin, PhD^{7*}, Robert M. Rifkin, MD⁸, Sikander Ailawadhi, MD⁹, Hans C. Lee, MD¹⁰, Howard R. Terebelo, DO¹¹, Brian G.M. Durie, MD¹², Mohit Narang, MD^{13*}, Kathleen Toomey, MD^{14*}, Cristina Gasparetto, MD¹⁵, Lynne I. Wagner, PhD^{16*} and Sundar Jagannath, MD^{17*}</p> <p>¹ Bristol Myers Squibb, Princeton, NJ ² Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI ³ Department of Haematology, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, United Kingdom ⁴ Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany ⁵ Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland ⁶ Indiana University School of Medicine, Indianapolis, IN ⁷ University of South Carolina, Columbia, SC ⁸ Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO ⁹ Mayo Clinic, Jacksonville, FL ¹⁰ The University of Texas MD Anderson Cancer Center, Houston, TX ¹¹ Providence Cancer Institute, Southfield, MI ¹² Cedars-Sinai Medical Center, Los Angeles, CA ¹³ US Oncology Research, Columbia, MD ¹⁴ Steeplechase Cancer Center, Somerville, NJ ¹⁵ Duke University Medical Center, Durham, NC ¹⁶ Wake Forest School of Medicine, Winston-Salem, NC ¹⁷ Mount Sinai Hospital, New York, NY</p>	<p>117 Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry</p>	<p>Oral</p>	<p>Saturday, December 11, 2021, 10:00 AM</p>	<p>905. Outcomes Research—Lymphoid Malignancies: Multiple Myeloma and Other Plasma Cell Disorders</p>	<p>https://ash.confex.com/ash/2021/webprogram/Paper146830.html</p>

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH

Authors	Title	Presentation Type	Date	Session	Link
<p>Felipe Samaniego, MD¹, John M. Burke, MD², Daruka Mahadevan, MD, PhD³, Mohamad Cherry, MD, MS⁴, Ahad A. Sadiq, MD^{5*}, M. Zach Koontz, MD^{6*}, Jose C. Villasboas, MD⁷, Erin Reid, MD, MS⁸, Elizabeth Cull, MD^{9*}, Victor Priego, MD^{10*}, Lindsey E. Roeker, MD, MSCE¹¹, Patrick Cobb, MD¹², Jason Melear, MD¹³, Paul Conkling, MD^{14*}, David Cosgrove, MD^{15*}, Hongying Zhang, MD, PhD^{16*}, Nasrin Rastgoo, PhD^{16*}, Khalid Benbatoul, BS^{16*}, Donna Nguyen Haney, MS^{16*}, Yuying Jin, PhD^{16*}, Jotin Marango, MD., PhD^{16*}, Stephen B. Howell, MD⁸, William G. Rice, PhD¹⁶ and Rafael Bejar, MD, PhD^{8,16}</p> <p>¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX ² US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO ³ University of Texas Health, San Antonio, Mays Cancer Center, San Antonio, TX ⁴ Hematology and Medical Oncology, Morristown Medical Center, Morristown, NJ ⁵ Fort Wayne Medical Oncology, Fort Wayne, IN ⁶ Pacific Cancer Care, Monterey, CA ⁷ Division of Hematology, Mayo Clinic, Rochester, MN ⁸ Moores Cancer Center, University of California San Diego Health, La Jolla, CA ⁹ Greenville Health System, Greenville, SC ¹⁰ Regional Cancer Care Associates, Hackensack, NJ ¹¹ Memorial Sloan Kettering Cancer Center, New York, NY ¹² St. Vincent Healthcare, Billings, MT ¹³ Texas Oncology-Austin Midtown, Austin, TX ¹⁴ Virginia Oncology Associates, Norfolk, VA ¹⁵ Northwest Cancer Specialists/Compass Oncology, Vancouver, WA ¹⁶ Aptose Biosciences, Inc., San Diego, CA</p>	<p>1355 A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies</p>	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper148827.html
<p>Sudhir Manda, MD¹, Bertrand Anz III, MD^{2*}, Christopher Benton, MD^{3*}, E. Randolph Brown, MD⁴, Habte Yimer, MD⁵, John Renshaw, MD^{6*}, George F. Geils Jr., MD⁷, Jose Cruz, MD^{8*}, Suzanne Fanning, DO⁹, Jason Melear, MD¹⁰, Jeff P. Sharman, MD¹¹, Kingston Kang, PhD^{12*}, Anders Svensson, MD^{12*}, Madhavi Pai, MBBS, MS^{12*} and William Donnellan, MD¹³</p> <p>¹ Arizona Oncology, The US Oncology Network, Tucson, AZ ² Tennessee Oncology, Chattanooga, TN ³ Rocky Mountain Cancer Centers, The US Oncology Network, Englewood, CO ⁴ Oncology Hematology Care, Inc., Cincinnati, OH ⁵ Texas Oncology-Tyler, The US Oncology Network, Tyler, TX ⁶ Texas Oncology-San Antonio Medical Center, The US Oncology Network, San Antonio, TX ⁷ Charleston Oncology, Charleston, SC ⁸ Methodist Physicians Texas Transplant Specialists, San Antonio, TX ⁹ Prisma Health Cancer Institute, Greenville, SC ¹⁰ Texas Oncology-Austin Midtown, Austin, TX ¹¹ Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR ¹² AbbVie, Inc., North Chicago, IL ¹³ Sarah Cannon Research Institute, Nashville, TN</p>	<p>1265 Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia</p>	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper144886.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada
* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
Christopher R. Flowers, MD ¹ , David Andorsky, MD^{2*}, John M. Burke, MD³ , James R. Cerhan, MD, PhD ⁴ , David L. Grinblatt, MD ⁵ , Chris L. Pashos ^{6*} , Kathleen Toomey, MD ^{7*} , Andrew D. Zelenetz, MD, PhD ⁸ , Kristen Sullivan ^{9*} , E. Dawn Flick ^{9*} , Pavel Kiselev ^{9*} , Mark Kaplan ^{9*} and Jung Ryun Ahn, MS ^{9*} ¹ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX ² US Oncology - Rocky Mountain Cancer Centers, Boulder, CO ³ US Oncology - Rocky Mountain Cancer Centers, Aurora, CO ⁴ Mayo Clinic, Rochester, MN ⁵ Northshore University, Evanston, IL ⁶ Genesis Research, Winchester, MA ⁷ Steeplechase Cancer Center, RWJ-Somerset, Somerville, NJ ⁸ Memorial Sloan Kettering Cancer Center, New York, NY ⁹ Bristol Myers Squibb, Princeton, NJ	1460 Connect [®] Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper145135.html
Jerome Goldschmidt, MD^{1*} , Alisha Monnette, PhD ^{2*} , Ping Shi ^{3*} , Divea Venkatasetty ^{3*} , Huan Huang ^{4*} and Marc Chioda ^{4*} ¹ Blue Ridge Cancer Care/US Oncology Research, Blacksburg, VA ² Ontada, New Orleans, LA ³ Ontada, The Woodlands, TX ⁴ G1 Therapeutics, Inc., Research Triangle Park, NC	1913 Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	901. Health Services Research—Non-Malignant Conditions: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper148057.html
Matthew S. Davids, MD, MMSc ¹ , Anthony R. Mato, MD ² , Juliette Hum ^{3*} , Susana Wargo ^{3*} , Ugochinyere Emeribe ^{4*} , Mina Shahkarami ^{5*} , Kevin Sokolowski ^{6*} , Juliana M.L. Biondo ^{7*} , Sarang Abhyankar ^{7*} , Rick Hermann ^{4*} and Jeff P. Sharman, MD⁸ ¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA ² Memorial Sloan Kettering Cancer Center, New York, NY ³ AstraZeneca, Mississauga, ON, Canada ⁴ AstraZeneca, Gaithersburg, MD ⁵ AstraZeneca, South San Francisco, CA ⁶ AbbVie, North Chicago, IL ⁷ Genentech Inc., South San Francisco, CA ⁸ Willamette Valley Cancer Institute and US Oncology Research Center, Eugene, OR	1553 Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper148155.html
Rachael M. Andrie ^{1*} , John M. Burke, MD² , Ian W. Flinn, MD, PhD ³ , John P. Leonard, MD ⁴ , Jeff P. Sharman, MD⁵ , Timothy A. Quill ^{1*} , Kristen Rosenthal, PhD ^{1*} and Christopher R. Flowers, MD ⁶ ¹ Clinical Care Options, LLC, Reston, VA ² US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO ³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN ⁴ Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY ⁵ Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR ⁶ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX	1922 Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	902. Health Services Research—Lymphoid Malignancies: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper152937.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Mazyar Shadman, MD, MPH^{1*}, Ian W. Flinn, MD, PhD², Moshe Y. Levy, MD³, Ryan Porter, MD^{4*}, John M. Burke, MD⁵, Jennifer L. Cultrera, MD^{6*}, Jamal Misleh, MD^{7*}, Syed F. Zafar, MD⁸, Benjamin Freeman, MD^{9*}, Subramanya S. Rao, MD^{10*}, Habte Yimer, MD¹¹, Arvind Chaudhry, MD, PhD^{12*}, Mitul D. Gandhi, MD¹³, Troy H. Guthrie, MD^{14*}, Edwin Kingsley, MD¹⁵, Praveen K. Tumula, MD, FACP¹⁶, Sudhir Manda, MD¹⁷, Dih-Yih Chen, MD^{18*}, Aileen Cohen, MD, PhD^{18*}, Kunthel By, MD^{18*}, Linlin Xu, PhD^{18*}, Ye Liu, PhD^{18*} and Jeff P. Sharman, MD¹⁹</p> <p>¹ Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA ² Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN ³ Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX ⁴ SSM Health Dean Medical Group, Madison, WI ⁵ Rocky Mountain Cancer Centers, Aurora, CO ⁶ Florida Cancer Specialists & Research Institute, Leesburg, FL ⁷ Medical Oncology Hematology Consultants PA, Newark, DE ⁸ Florida Cancer Specialists & Research Institute, Fort Myers, FL ⁹ Summit Medical Group, Florham Park, NJ ¹⁰ Alpha Med Physicians Group, Tinley Park, IL ¹¹ Texas Oncology, Tyler, TX ¹² Summit Cancer Centers, Spokane, WA ¹³ Virginia Cancer Specialists, Gainesville, VA ¹⁴ GenesisCare, Jacksonville, FL ¹⁵ Comprehensive Cancer Centers of Nevada, Las Vegas, NV ¹⁶ Texas Oncology, Amarillo, TX ¹⁷ Arizona Oncology/US Oncology Research, Tucson, AZ ¹⁸ BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA ¹⁹ Willamette Valley Cancer Institute and Research Center, Eugene, OR</p>	1410 Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper148544.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>John E. Godwin, MD¹, Bassam Mattar, MD^{2*}, Michael Maris, MD³, Carlos Bachier, MD⁴, Don Stevens, MD⁵, Daanish Hoda, MD⁶, Juan C. Varela, MD, PhD⁷, Mohamad Cherry, MD, MS⁸, Suzanne Fanning, DO⁹, James Essell, MD¹⁰, Habte Yimer, MD¹¹, Jay Courtright, MD^{12*}, Jeff P. Sharman, MD¹³, Ricardo Espinola, MD^{14*}, Connor Mailley, MSc, MBAC^{15*}, Ariel Avilion, PhD^{16*}, Ken Ogasawara, PhD, MPH^{15*}, San-San Ou, MS^{16*} and Paul Shaughnessy, MD¹⁷</p> <p>¹ Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR ² Department of Internal Medicine, Cancer Center of Kansas, Wichita, KS ³ Department of Hematology/Oncology, Colorado Blood and Cancer Institute and Sarah Cannon Research Institute, Denver, CO ⁴ Department of Hematology, Sarah Cannon Center for Blood Cancer, Nashville, TN ⁵ Department of Medical Oncology, Norton Healthcare, Louisville, KY ⁶ Department of Hematology/Oncology, Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, UT ⁷ Blood and Marrow Transplant Program, Advent Health, Orlando, FL ⁸ Department of Hematology Oncology, Atlantic Health System, Carol Simon Cancer Center, Morristown, NJ ⁹ Department of Hematology, Prisma Health, Greenville, SC ¹⁰ Departments of Medical Oncology, Hematology, and Blood and Marrow Transplantation, Oncology Hematology Care, Cincinnati, OH ¹¹ Departments of Hematology, Medical Oncology, Texas Oncology-Tyler, Tyler, TX ¹² Department of Hematology, Medical Oncology, Texas Oncology, Medical City Dallas, Dallas, TX ¹³ Willamette Valley Cancer Institute/US Oncology, Eugene, OR ¹⁴ Bristol Myers Squibb, San Diego, CA ¹⁵ Bristol Myers Squibb, Princeton, NJ ¹⁶ Bristol Myers Squibb, Seattle, WA ¹⁷ Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, TX</p>	<p>1762 Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)</p>	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	704. Cellular Immunotherapies: Clinical: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper148792.html
<p>Roger Lyons, MD¹, David Lessen, MD², Salman Fazal, MD³, Robyn Scherber, MD, MPH⁴, Patricia Kalafut, PhD^{4*}, Haobo Ren, PhD^{4*} and Ellen Ritchie, MD⁵</p> <p>¹ Texas Oncology, San Antonio, TX ² Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL ³ Allegheny Health Network Cancer Institute, Pittsburgh, PA ⁴ Incyte Corporation, Wilmington, DE ⁵ Division of Hematology and Oncology, Weill Cornell Medical College New York Presbyterian, New York, NY</p>	<p>1497 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)</p>	Program: Oral and Poster Abstracts	Saturday, December 11, 2021, 5:30 PM-7:30 PM	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper145909.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Jacqueline Barrientos, MD, MS¹, Anthony R. Mato, MD², Nilanjan Ghosh, MD, PhD³, Jeff P. Sharman, MD⁴, Meghan Gutierrez, BA^{5*}, Maoko Naganuma, MSc^{6*}, Sandhya Upasani, MS^{6*}, Divi Alagappan, PhD^{7*}, Qing Huang, PhD^{7*}, Alex Young, PharmD^{6*} and Danielle M. Brander, MD⁸</p> <p>¹ Division of Medical Oncology and Hematology, Northwell Health Cancer Institute Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY ² Memorial Sloan Kettering Cancer Center, New York, NY ³ Levine Cancer Institute, Charlotte, NC ⁴ Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR ⁵ Lymphoma Research Foundation, New York, NY ⁶ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA ⁷ Janssen Scientific Affairs, LLC, Horsham, PA ⁸ Duke University Health System, Durham, NC</p>	<p>1976 Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for CLL/SLL from the informCLL Real-World Registry</p>	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	905. Outcomes Research—Lymphoid Malignancies: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper147084.html
<p>Amit Verma, MD¹, Andrew M. Brunner, MD^{2*}, Gregory Pennock^{3*}, Dragana McMullen^{3*}, Mark Wade^{3*}, Huyuan Yang^{3*}, Yuran Xie^{3*}, Cliff Whatcott^{3*}, Jason Foulks^{3*} and Jason Melear, MD⁴</p> <p>¹ Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY ² Massachusetts General Hospital, Boston, MA ³ Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA ⁴ Texas Oncology-Austin Midtown, Austin, TX</p>	<p>1534 Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes</p>	Poster	Saturday, December 11, 2021, 5:30 PM-7:30 PM	637. Myelodysplastic Syndromes — Clinical and Epidemiological: Poster I	https://ash.confex.com/ash/2021/webprogram/Paper147594.html
<p>John M. Burke, MD¹, Gustavo Fonseca, MD^{2*}, Wojciech Jurczak, MD, PhD^{3*}, Jason Melear, MD⁴, Miguel Islas-Ohlmayer, MD⁵, James A. Reeves, MD^{6*}, Parameswaran Venugopal, MD⁷, Tomasz Wróbel, MD, PhD⁸, Don Stevens, MD⁹, John M. Pagel, MD, PhD¹⁰, Jerome Goldschmidt, MD^{11*}, Hari P. Miskin, MSc¹², Peter Sportelli, BS¹², Owen A. O'Connor, MD, PhD^{12*} and Nilanjan Ghosh, MD, PhD¹³</p> <p>¹ Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO ² Florida Cancer Specialists North/Sarah Cannon Research Institute, St. Petersburg, FL ³ Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland ⁴ Texas Oncology, Austin, TX ⁵ Oncology Hematology Care, Cincinnati, OH ⁶ Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL ⁷ Rush University Medical Center, Chicago, IL ⁸ Department of Hematology, Wrocław Medical University, Wrocław, Poland ⁹ Norton Cancer Institute, Louisville, KY ¹⁰ Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA ¹¹ Blue Ridge Cancer Care/US Oncology Research, Blacksburg, VA ¹² TG Therapeutics, Inc., New York, NY ¹³ Department of Hematology, Lymphoma Division, Levine Cancer Institute/ Atrium Health, Charlotte, NC</p>	<p>527 Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Clinically Relevant Abstract</p>	Oral	Sunday, December 12, 2021, 5:30 PM	626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations	https://ash.confex.com/ash/2021/webprogram/Paper151054.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Paul G. Richardson, MD¹, Thierry Facon^{2*}, Christopher P. Venter^{3*}, Nizar J. Bahlis, MD⁴, Fritz Offner, MD, PhD⁵, Darrell White^{6*}, Lionel Karlin^{7*}, Lotfi Benboubker^{8*}, Sophie Rigaudeau, MD^{9*}, Eric Voog^{10*}, Sung-Soo Yoon, MD¹¹, Kenshi Suzuki, MD, PhD¹², Hirohiko Shibayama, MD, PhD¹³, Xiaoquan Zhang, MD^{14*}, Arun Kumar^{14*}, Philip Twumasi-Ankrah^{14*}, Richard Labotka, MD¹⁴, Robert M. Rifkin, MD¹⁵, Sagar Lonial, MD, FACP¹⁶, Shaji K. Kumar, MD¹⁷, S. Vincent Rajkumar, MD^{17*} and Philippe Moreau, MD^{18*}</p> <p>¹ Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA ² Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France ³ Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada ⁴ Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada ⁵ UZ Gent, Gent, Belgium ⁶ QEII Health Sciences Center and Dalhousie University, Halifax, NS, Canada ⁷ Hôpital Lyon Sud, Pierre-Benite, France ⁸ CHRU TOURS, Tours, France ⁹ Centre Hospitalier de Versailles André Mignot, Le Chesnay, France ¹⁰ Clinique Victor Hugo, Le Mans, France ¹¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South) ¹² Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan ¹³ Osaka University Graduate School of Medicine, Suita, Japan ¹⁴ Takeda Development Center Americas, Inc. (TDCA), Lexington, MA ¹⁵ US Oncology Research - Rocky Mountain Cancer Centers, Denver, CO ¹⁶ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA ¹⁷ Mayo Clinic, Rochester, MN ¹⁸ Centre Hospitalier Universitaire de Nantes, Nantes, France</p>	<p>2733 Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper148481.html
<p>Robert M. Rifkin, MD¹, Stephen J. Noga, MD, PhD², Saulius K. Girnius, MD³, Kimberly Bogard, PharmD^{4*}, Sudhir Manda, MD⁵, Habte Yimer, MD⁶, Presley Whidden^{4*}, Ruemu E. Birhiray, MD⁷, Philip Twumasi-Ankrah^{2*}, Yikun Guo^{2*}, Rami Oweria, MD^{8*}, Leon Bernal-Mizrachi, MD⁹ and Roger Lyons, MD¹⁰</p> <p>¹ Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO ² Takeda Development Center Americas, Inc. (TDCA), Lexington, MA ³ TriHealth Cancer Institute, Cincinnati, OH ⁴ Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA ⁵ Arizona Oncology/US Oncology Research, Tucson, AZ ⁶ Texas Oncology/US Oncology Research, Tyler, TX ⁷ Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN ⁸ Woodlands Medical Specialists-Pensacola, Pensacola, FL ⁹ Grady Health System, Atlanta, GA ¹⁰ Texas Oncology/US Oncology Research, San Antonio, TX</p>	<p>2726 Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation</p>	Program: Oral and Poster Abstracts	Sunday, December 12, 2021, 6:00 PM-8:00 PM	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper150094.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Hun Ju Lee¹, Ian W. Flinn, MD, PhD², Jason Melear, MD³, Rod Ramchandren, MD⁴, Judah Friedman, MD^{5*}, John M. Burke, MD³, Yuliya Linhares^{3*}, Matthew R. Peterson, MD^{6*}, Mihir Raval, MD³, Rangaswamy Chintapatla, MD⁷, Tatyana A. Feldman, MD⁸, Habte Yimer, MD³, Miguel Islas-Ohlmayer, MD^{3,9}, Asad Dean^{3*}, Vishal Rana, MD^{10*}, Mitul D. Gandhi, MD³, John Renshaw, MD^{3*}, Amanda L. Gillespie-Twardy, MD^{3*}, Linda Ho, MD^{11*}, Michelle A. Fanale, MD¹¹, Wenchuan Guo^{11*} and Christopher A. Yasenachak, MD¹²</p> <p>¹ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX ² Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN ³ US Oncology Research, The Woodlands, TX ⁴ University of Tennessee Medical Center, Knoxville, TN ⁵ University Hospitals Seidman Cancer Center, Cleveland, OH ⁶ Brooke Army Medical Center, Fort Sam Houston, TX ⁷ Kadlec Clinic, Kennewick, WA ⁸ Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ ⁹ Oncology Hematology Care, Cincinnati, OH ¹⁰ University of Colorado Health Hematology and Oncology, Colorado Springs, CO ¹¹ Seagen Inc., Bothell, WA ¹² Willamette Valley Cancer Institute and Research Center, Eugene, OR</p>	<p>2454 Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	624. Hodgkin Lymphomas and T/ NK Cell Lymphomas: Clinical and Epidemiological: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper147891.html
<p>Toby A. Eyre^{1*}, Nirav N. Shah, MD², Steven Le Guill³, Martin H. Dreyling, MD, PhD⁴, Elisabeth Vandenberghe, MD, PhD⁵, Wojciech Jurczak, MD, PhD^{6*}, Yucai Wang, MD⁷, Chan Yoon Cheah⁸, Mitul D. Gandhi, MD⁹, Christopher H. Chay, MD^{10*}, Jeff P. Sharman, MD¹¹, David Jacob Andorsky, MD¹², Ming Yin^{13*}, Minna Balbas^{13*}, Jennifer Kherani^{13*} and Michael L. Wang, MD¹⁴</p> <p>¹ Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom ² Medical College of Wisconsin, Milwaukee, WI ³ Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France ⁴ Department of Internal Medicine III, LMU Hospital, Munich, Germany ⁵ Hope Directorate St. James Hospital, Dublin, Ireland ⁶ Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland ⁷ Division of Hematology, Mayo Clinic, Rochester, MN ⁸ Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia ⁹ Virginia Cancer Specialists, Fairfax, VA ¹⁰ Messino Cancer Centers, Asheville, NC ¹¹ Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR ¹² Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO ¹³ Loxo Oncology at Lilly, Stamford, CT</p>	<p>2422 BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper145920.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Sagar Lonial, MD, FACP¹, Stefano R. Tarantolo, MD², Ralph V. Boccia, MD³, Habte Yimer, MD⁴, Moshe Y. Levy, MD⁵, Rafat Abonour, MD⁶, Meera Mohan, MD⁷, Vivek Roy, MD⁸, Jeremy T. Larsen⁹, Saulius K. Girnius, MD¹⁰, Cara A. Rosenbaum, MD^{11*}, Omar Nadeem, MD¹², Deborah Berg, RN, MSN¹³, Bo Chao^{13*}, Allison J. Berger, PhD^{13*}, Akito Nakamura^{13*}, Yuhong Zhang^{13*}, Keli Song^{13*}, Christine K. Ward^{13*}, Igor Proscurshim^{13*} and Shaji K. Kumar, MD¹⁴</p> <p>¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA ² Nebraska Cancer Specialists, Omaha, NE ³ The Center for Cancer and Blood Disorders, Bethesda, MD ⁴ Texas Oncology-Tyler/US Oncology Research, Tyler, TX ⁵ Baylor University Medical Center, Dallas, TX ⁶ Indiana University School of Medicine, Indianapolis, IN ⁷ Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI ⁸ Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL ⁹ Division of Hematology, Mayo Clinic, Phoenix, AZ ¹⁰ TriHealth Cancer Institute, Cincinnati, OH ¹¹ Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY ¹² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA ¹³ Takeda Development Center Americas, Inc. (TDCA), Lexington, MA ¹⁴ Division of Hematology, Mayo Clinic, Rochester, MN</p>	<p>2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper148385.html
<p>Barry Paul, MD, MS¹, Michaela Liedtke, MD², Jorge Monge, MD^{3*}, Maria Chaudhry, MBBS⁴, Robert M. Rifkin, MD⁵, Mitul D. Gandhi, MD⁶, Jack Khouri, MD⁷, Andrew Kin, MD⁸, Tibor Kovacsovics, MD⁹, Moshe Y. Levy, MD¹⁰, Ann Mohrbacher, MD^{11*}, William Schmidt, MD^{12*}, David S. Siegel, MD, PhD¹³, Rebecca W. Silbermann, MD¹⁴, Anna Louise Byrne, MS¹⁵, Tina Ncube, BSC Hons^{15*}, Michael Murphy, MS^{15*}, Lin Gu, MS^{15*}, Nishanthan Rajakumaraswamy, MD^{15*}, Mark Chao, MD, PhD¹⁵ and Saad Z. Usmani, MD, MBA, FACP¹</p> <p>¹ Levine Cancer Institute, Charlotte, NC ² Stanford Cancer Institute, Stanford, CA ³ Weill Cornell Medicine, New York, NY ⁴ The Ohio State University College of Medicine, Columbus, OH ⁵ The US Oncology Network, Denver, CO ⁶ Virginia Cancer Specialists, Fairfax, VA ⁷ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH ⁸ Barbara Ann Karmanos Cancer Institute, Detroit, MI ⁹ Huntsman Cancer Institute and Hospital, Salt Lake City, UT ¹⁰ Baylor University Medical Center, Dallas, TX ¹¹ University of Southern California, Los Angeles, CA ¹² Bend Memorial Clinic, Bend, OR ¹³ John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ ¹⁴ Oregon Health and Science University, Portland, OR ¹⁵ Gilead Sciences, Inc., Foster City, CA</p>	<p>2757 A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper145903.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Tyrel Phillips, MD¹, Kristen Migliaccio-Walle^{2*}, Kristina S. Yu, PhD, MPH, RPh^{3*}, Brian Bloudek, MS^{2*}, Nicholas Liu, PharmD^{3*}, Michelle A. Fanale, MD³ and John M. Burke, MD⁴</p> <p>¹ Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI ² Curta Inc., Seattle, WA ³ Seagen Inc., Bothell, WA ⁴ US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO</p>	2440 An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper147308.html
<p>John M. Burke, MD¹, Kristina S. Yu, PhD, MPH, RPh^{2*}, Uche Mordi, PharmD^{3*}, Brian Bloudek, MS^{3*}, Nicholas Liu, PharmD^{2*}, Michelle A. Fanale, MD² and Tyrel Phillips, MD⁴</p> <p>¹ US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO ² Seagen Inc., Bothell, WA ³ Curta Inc., Seattle, WA ⁴ Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI</p>	2466 An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper148004.html
<p>James E. Hoffman, MD¹, Brea Lipe, MD², Jason Melear, MD³, Michaela Liedtke, MD⁴, Mark A. Schroeder, MD⁵, Ruben Niesvizky, MD⁶, Michael H. Tomasson, MD⁷, Christopher A. Yasenchak, MD⁸, Damian J. Green, MD⁹, Hong Li^{10*}, Yinghui Wang, MS^{10*}, Phoenix Ho, MD¹⁰ and Al-Ola Abdallah, MD¹¹</p> <p>¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL ² Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY ³ Texas Oncology, Austin, TX ⁴ Stanford University Medical Center, Stanford, CA ⁵ Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO ⁶ Weill Cornell Medicine, New York, NY ⁷ University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA ⁸ Willamette Valley Cancer Institute and Research Center, Eugene, OR ⁹ Fred Hutchinson Cancer Research Center, Seattle, WA ¹⁰ Seagen Inc., Bothell, WA ¹¹ University of Kansas Medical Center, Kansas City, KS</p>	2740 SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Pro prospective Therapeutic Trials: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper146047.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Connie Lee Batlevi, MD, PhD¹, Steven I. Park, MD², Loretta Nastoupil, MD³, Tycel Phillips, MD⁴, Jennifer E. Amengual, MD⁵, David Andorsky, MD^{6*}, Philip Campbell, MB, ChB⁷, Pamela McKay, MD^{8*}, John M. Pagel, MD, PhD⁹, John P. Leonard, MD¹⁰, Jay Yang, PhD^{11*}, Heather O'Connor, MD^{11*}, Anthony Hamlett, PhD^{11*}, Deyaa Adib, MD^{11*} and Franck Morschhauser, MD, PhD^{12*}</p> <p>¹ Memorial Sloan Kettering Cancer Center, New York, NY ² Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC ³ MD Anderson Cancer Center, Houston, TX ⁴ University of Michigan, Ann Arbor, MI ⁵ Columbia University Irving Medical Center, New York, NY ⁶ Rocky Mountain Cancer Centers, Boulder, CO ⁷ Barwon Health, University Hospital Geelong, Geelong, VIC, Australia ⁸ Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom ⁹ Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA ¹⁰ Weill Cornell Medicine, New York, NY ¹¹ Epizyme, Inc., Cambridge, MA ¹² Univ. Lille, CHU Lille, EA 7365—GRITA—Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France</p>	<p>2207 Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma</p>	Poster	Sunday, December 12, 2021, 6:00 PM-8:00 PM	602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster II	https://ash.confex.com/ash/2021/webprogram/Paper148199.html
<p>Frederick Lansigan, MD¹, David Jacob Andorsky, MD², Morton Coleman, MD, FACP^{3*}, Abdurraheem Yacoub, MD⁴, Jason Melear, MD⁵, Suzanne Fanning, DO⁶, Kathryn S. Kolibaba, MD⁷, Christopher M. Reynolds, MD, BA⁸, Grzegorz S. Nowakowski, MD⁹, Mecide Gharibo, MD¹⁰, Jung Ryun Ahn, MD^{10*}, Ju Li, PhD^{10*}, Mathias J. Rummel, MD, PhD^{11*} and Jeff P. Sharman, MD¹²</p> <p>¹ Dartmouth-Hitchcock Medical Center, Lebanon, NH ² Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO ³ Clinical Research Alliance Inc., Weill Cornell Medicine, New York, NY ⁴ University of Kansas Cancer Center, Westwood, KS ⁵ Texas Oncology — Austin, US Oncology Research, Austin, TX ⁶ Prisma Health, US Oncology Research, Greenville, SC ⁷ US Oncology Research, Vancouver, WA ⁸ IHA Hematology Oncology Consultants — Ann Arbor, Ypsilanti, MI ⁹ Mayo Clinic, Rochester, MN ¹⁰ Bristol Myers Squibb, Princeton, NJ ¹¹ Justus-Liebig-Universität, Giessen, Germany ¹² Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR</p>	<p>812 Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma</p>	Oral	Monday, December 13, 2021, 4:45 PM	623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Follicular Lymphoma: Advances in Treatment Approaches	https://ash.confex.com/ash/2021/webprogram/Paper145640.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
Ryan Jacobs, MD ^{1*} , Wojciech Jurczak, MD, PhD ^{2*} , Ian W. Flinn, MD, PhD ³ , Sebastian Grosicki, MD, PhD ^{4*} , Krzysztof Giannopoulos, MD, PhD ^{5*} , Tomasz Wróbel, MD, PhD ⁶ , Syed F. Zafar, MD ⁷ , Jennifer L. Cultrera, MD ^{8*} , Suman Kambhampati, MD ^{9*} , Alexey V. Danilov, MD, PhD ¹⁰ , John M. Burke, MD¹¹ , Jerome Goldschmidt, MD^{12*} , Douglas F. Beach, MD ^{13*} , Scott F. Huntington, MD, MPH ¹⁴ , Javier Pinilla Ibarz, MD, PhD ¹⁵ , Jeff P. Sharman, MD¹⁶ , Tanya Siddiqi, MD ^{17*} , Danielle M. Brander, MD ¹⁸ , Mazyar Shadman, MD ¹⁹ , John M. Pagel, MD, PhD ²⁰ , Monika Dlugosz-Danecka, MD, PhD ^{21*} , Nilanjan Ghosh, MD, PhD ¹ , Kathryn S. Kolibaba, MD ^{22*} , Peter Sportelli, BS ²² , Hari P. Miskin, MSc ²² , Owen A. O'Connor, MD, PhD ^{22*} , Michael S. Weiss ^{22*} and John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath ²³	3726 Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper147460.html

¹ Department of Hematology, Lymphoma Division, Levine Cancer Institute/ Atrium Health, Charlotte, NC
² Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland
³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
⁴ Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
⁵ Hematology Department, St. John's Cancer Centre, Lublin, Poland
⁶ Department of Hematology, Wroclaw Medical University, Wroclaw, Poland
⁷ Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL
⁸ Florida Cancer Specialists North/Sarah Cannon Research Institute, St. Petersburg, FL
⁹ Sarah Cannon Research Institute At Research Medical Ctr, Kansas City, MO
¹⁰ Knight Cancer Institute, Oregon Health & Science University, Portland, OR
¹¹ Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO
¹² Blue Ridge Cancer Care/US Oncology Research, Blacksburg, VA
¹³ Pennsylvania Hospital, University of Pennsylvania, Philadelphia, PA
¹⁴ Yale Cancer Center, New Haven, CT
¹⁵ Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
¹⁶ Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR
¹⁷ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
¹⁸ Duke Cancer Institute, Duke University Health System, Durham, NC
¹⁹ Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
²⁰ Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
²¹ Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland
²² TG Therapeutics, Inc., New York, NY
²³ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada
 * Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Javier Pinilla Ibarz, MD, PhD¹, Wojciech Jurczak, MD, PhD^{2*}, Suman Kambhampati, MD^{3*}, Ewa Lech Maranda, MD, PhD^{4*}, Tomasz Wróbel, MD, PhD⁵, Jeff P. Sharman, MD⁶, Syed F. Zafar, MD⁷, Marc Hoffmann, MD⁸, Scott F. Huntington, MD, MPH⁹, Ryan Jacobs, MD^{10*}, Osnat Bairey, MD^{11*}, Chris Rowland, PhD^{12*}, Hari P. Miskin, MSc¹², Peter Sportelli, BS¹², Michael S. Weiss^{12*}, Owen A. O'Connor, MD, PhD^{12*} and Ian W. Flinn, MD, PhD¹³</p> <p>¹ Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL ² Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland ³ Sarah Cannon Research Institute At Research Medical Ctr, Kansas City, MO ⁴ Institute of Hematology and Transfusion Medicine, Warsaw, Poland ⁵ Department of Hematology, Wrocław Medical University, Wrocław, Poland ⁶ Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR ⁷ Florida Cancer Specialists South / Sarah Cannon Research Institute, Fort Myers, FL ⁸ University of Kansas Medical Center, Kansas City, KS ⁹ Yale Cancer Center, New Haven, CT ¹⁰ Department of Hematology, Lymphoma Division, Levine Cancer Institute/ Atrium Health, Charlotte, NC ¹¹ Davidoff Cancer Center, Rabin Medical Center Beilinson Hospital, Rabin Medical Center Beilinson Campus, Petah Tikva, Israel ¹² TG Therapeutics, Inc., New York, NY ¹³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN</p>	<p>3748 Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial</p>	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper151292.html
<p>Ian W. Flinn, MD, PhD¹, David Andorsky, MD^{2*}, Jason Melear, MD³, Sudhir Manda, MD⁴, Bertrand Anz III, MD^{5*}, Kathryn Kolibaba, MD^{6*}, Habte Yimer, MD⁷, John M. Burke, MD⁸, Suzanne Fanning, DO⁹, Jay Courtright, MD^{10*}, Miguel Islas-Ohlmayer, MD^{11*}, Suman Kambhampati, MD^{12*}, Tamas Vizkelely, MD^{13*}, John Pesko, PhD^{13*}, Brenda Chyla, PhD¹³, Dingfeng Jiang, MD, PhD^{13*} and Jeff P. Sharman, MD¹⁴</p> <p>¹ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN ² Rocky Mountain Cancer Centers, Boulder, CO ³ Texas Oncology-Austin Midtown, Austin, TX ⁴ Arizona Oncology Associates, PC-HOPE, Tucson, AZ ⁵ Tennessee Oncology Chattanooga, Chattanooga, TN ⁶ US Oncology Research, The Woodlands, TX ⁷ Texas Oncology-Tyler, Tyler, TX ⁸ Rocky Mountain Cancer Centers, Aurora, CO ⁹ Prisma Health, Greenville, SC ¹⁰ Texas Oncology-Dallas, Dallas, TX ¹¹ Oncology Hematology Care, Inc., Cincinnati, OH ¹² Sarah Cannon Cancer Institute, HCA Midwest Health, Research Medical Center, Kansas City, MO ¹³ AbbVie Inc., North Chicago, IL ¹⁴ Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR</p>	<p>3725 Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study</p>	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper147258.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada
* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>David Belada, MUDr, PhD^{1*}, Katerina Kopeckova, MUDr, PhD^{2*}, Juan Miguel Bergua Burgues, MD^{3*}, Don Stevens, MD⁴, Marc André, MD^{5*}, Ernesto Pérez Persona, MD^{6,7*}, Petra Pichler, MD^{8,9*}, Philipp B. Staber, MD, PhD¹⁰, Marek Trnety, MD¹¹, Bettina Brackertz, PhD^{12*}, Neha Shah, B. Pharmacy, MBA^{12*}, Andrea Sporchia, MD^{12*}, John M. Burke, MD¹³ and Grzegorz S. Nowakowski, MD¹⁴</p> <p>¹ 4th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic ² Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic ³ Hematology, Hospital San Pedro de Alcantara, Cáceres, Spain ⁴ Norton Cancer Institute - St. Matthews Campus, Louisville, KY ⁵ Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium ⁶ Osakidetza Basque Health Service, Araba University Hospital, Hematology department, Vitoria-Gasteiz, Spain ⁷ Bioaraba, Onco-hematology research group, Vitoria-Gasteiz, Spain ⁸ Department of Internal Medicine, University Hospital of St. Pölten, St. Pölten, Austria ⁹ Karl Landsteiner University of Health Sciences, Karl Landsteiner Institute for Nephrology and Hemato Oncology, St. Pölten, Austria ¹⁰ Medical University of Vienna, Department of Medicine I, Division of Hematology & Hemostaseology, Vienna, Austria ¹¹ Charles University General Hospital, Prague, Czech Republic ¹² MorphoSys AG, Planegg, Germany ¹³ Hematology, US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO ¹⁴ Division of Hematology, Mayo Clinic, Rochester, MN</p>	<p>3556 First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma</p>	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper148354.html
<p>Nancy L. Bartlett, MD¹, Christopher A. Yasenachak, MD², Khaleel Ashraf, MD^{3*}, William Harwin, MD^{4*}, Robert Sims, MD⁵ and Grzegorz S. Nowakowski, MD⁶</p> <p>¹ Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO ² Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR ³ Hematology and Oncology Associates of Alabama, Birmingham, AL ⁴ Sarah Cannon Research Institute, Fort Myers, FL ⁵ Seagen Inc., Bothell, WA ⁶ Division of Hematology, Mayo Clinic, Rochester, MN</p>	<p>3564 Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)</p>	Program: Oral and Poster Abstracts	Monday, December 13, 2021, 6:00 PM-8:00 PM	626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper151583.html
<p>Jeff P. Sharman, MD¹, Wojciech Jurczak, MD, PhD^{2*}, Catherine C. Coombs, MD³, Marisa Hill^{4*}, Denise Wang^{4*}, Nora C. Ku, MD^{4*}, Ananya Guntur, PhD^{4*}, Safi Shahda, MD^{4*}, Ching Ching Leow^{4*}, Paolo Ghia, MD, PhD⁵ and Anthony R. Mato, MD⁶</p> <p>¹ Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR ² Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland ³ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC ⁴ Loxo Oncology at Lilly, Stamford, CT ⁵ Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy ⁶ Memorial Sloan Kettering Cancer Center, New York, NY</p>	<p>3736 BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (Trial in Progress)</p>	Program: Oral and Poster Abstracts	Monday, December 13, 2021, 6:00 PM-8:00 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper145926.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>David Andorsky, MD^{1*}, Sarah Tomassetti², Yehuda E. Deutsch, MD³, E. Randolph Broun, MD⁴, Ghayas C. Issa, MD⁵, Moshe Y. Levy, MD⁶, Michael W. Deininger, MD, PhD⁷, Rodrigo Maegawa, MD, MBA^{8*}, Alok Shrestha^{9*} and Michael J. Mauro, MD⁹</p> <p>¹ Rocky Mountain Cancer Centers, Boulder, CO ² Harbor-UCLA Medical Center and The David Geffen School of Medicine at UCLA, Redondo Beach, CA ³ Department of Malignant Hematology and Cellular Therapy at Memorial Health System, Moffitt Cancer Center, Pembroke Pines, FL ⁴ Oncology Hematology Care, Inc., Cincinnati, OH ⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX ⁶ Baylor Scott & White Research Institute, Dallas, TX ⁷ Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT ⁸ Novartis Pharmaceuticals Corporation, East Hanover, NJ ⁹ Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY</p>	<p>3599 Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations</p>	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper147337.html
<p>Jakub Svoboda, MD¹, Jonathon B. Cohen, MD, MS², Chaitra S. Ujjani, MD³, David Andorsky, MD^{4*}, Andre H. Goy, MD^{5*}, Anita Kumar, MD⁶, Scott D. Ramsey, MD, PhD^{7*}, Mike Wallington^{8*}, James M. Eudicone^{9*}, Rick Hermann^{10*}, Victor Gonzalez, MA, MS^{11*}, Michael Wang, MD¹² and John M. Pagel, MD, PhD¹³</p> <p>¹ Hospital of the University of Pennsylvania, Philadelphia, PA ² Emory University, Atlanta, GA ³ University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA ⁴ Rocky Mountain Cancer Centers, Boulder, CO ⁵ Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ ⁶ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY ⁷ Fred Hutchinson Cancer Research Center, Seattle, WA ⁸ AstraZeneca, Cambridge, United Kingdom ⁹ AstraZeneca, Wilmington, DE ¹⁰ AstraZeneca, Gaithersburg, MD ¹¹ Lymphoma Research Foundation, New York, NY ¹² University of Texas MD Anderson Cancer Center, Houston, TX ¹³ Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA</p>	<p>4115 Clinician-Based Performance Status and Its Correlation with Patient-Reported Outcomes: Findings from a Prospective Observational Study in Patients with Mantle Cell Lymphoma</p>	Poster	Monday, December 13, 2021, 6:00 PM-8:00 PM	905. Outcomes Research—Lymphoid Malignancies: Poster III	https://ash.confex.com/ash/2021/webprogram/Paper146874.html

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Authors	Title	Presentation Type	Date	Session	Link
<p>Hervé Tilly, MD¹, Franck Morschhauser, MD, PhD^{2*}, Laurie H. Sehn, MD³, Jonathan W. Friedberg, MD⁴, Marek Trněný, MD⁵, Jeff P. Sharman, MD⁶, Charles Herbaux, MD⁷, John M. Burke, MD⁸, Matthew Matasar, MD^{9,10}, Shinya Rai, MD, PhD^{11*}, Koji Izutsu, MD, PhD^{12*}, Neha Mehta-Shah, MD¹³, Lucie Oberic, MD^{14*}, Adrien Chauchet, MD^{15*}, Wojciech Jurczak, PhD, MD¹⁶, Yuqin Song, MD^{17*}, Richard Greil, MD¹⁸, Larysa Mykhalska, MD^{19*}, Juan Miguel Bergua Burgués, MD^{20*}, Matthew C. Cheung, MD²¹, Antonio Pinto, MD^{22*}, Ho-Jin Shin, MD, PhD^{23*}, Greg Hapgood, MD, PhD^{24*}, Eduardo Munhoz, MD^{25*}, Pau Abrisqueta Costa, MD, PhD^{26*}, Jyh-Pyng Gau, MD^{27*}, Jamie Hirata, PharmD²⁸, Yanwen Jiang, PhD^{28*}, Mark Yan, PhD^{29*}, Calvin Lee, MD²⁸, Christopher R. Flowers, MD³⁰ and Gilles Salles, MD, PhD³¹</p> <p>¹ Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France ² Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France ³ BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada ⁴ Wilmot Cancer Institute, University of Rochester, Rochester, NY ⁵ First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic ⁶ Willamette Valley Cancer Institute/US Oncology, Eugene, OR ⁷ CHU de Montpellier, Montpellier, France ⁸ Rocky Mountain Cancer Centers/US Oncology, Aurora, CO ⁹ Memorial Sloan Kettering Cancer Center, New York, NY ¹⁰ Memorial Sloan Kettering Cancer Center, Montvale, NJ ¹¹ Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City, Japan ¹² National Cancer Center Hospital, Tokyo, Japan ¹³ Washington University in St. Louis, St. Louis, MO ¹⁴ Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, France ¹⁵ Department of Hematology, CHRU Besançon, Besançon, France ¹⁶ Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland ¹⁷ Peking University Cancer Hospital, Beijing, China ¹⁸ 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria ¹⁹ Clinical Hospital Feofaniya, Kyiv, Ukraine ²⁰ Hospital San Pedro de Alcántara, Cáceres, Spain ²¹ Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada ²² Hematology-Oncology & Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy ²³ Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of (South) ²⁴ Princess Alexandra Hospital, Brisbane, QLD, Australia ²⁵ Hospital Erasto Gaertner, Curitiba, Brazil ²⁶ Department of Hematology, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain ²⁷ Taipei Veterans General Hospital, Taipei, Taiwan ²⁸ Genentech, Inc., South San Francisco, CA ²⁹ F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada ³⁰ MD Anderson Cancer Center, Houston, TX ³¹ Memorial Kettering Cancer Center, New York, NY</p>	<p>LBA-1 The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma</p>	<p>General Session</p>	<p>Tuesday, December 14, 2021, 9:00 AM-10:30 AM</p>	<p>Late-Breaking Abstracts Session</p>	<p>https://ash.confex.com/ash/2021/webprogram/Paper154729.html</p>

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or Ontada

* Denotes non-member of ASH



Learn More

usoncology.com

ontada.com

researchopportunities@mckesson.com

281.863.1000

©2021 McKesson Corporation. All rights reserved.

USON-1550652-1121

